Contact this trialFirst, we need to learn more about you.
Duvelisib After CAR T-Cell Therapy for Lymphoma
Recruiting1 awardPhase 1
Saint Louis, Missouri
This trial is testing if a drug that reversibly inhibits PI3K is safe and effective in preventing cytokine release syndrome and enhancing the efficacy of CAR T-cells.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.